Rhythm Biosciences (ASX:RHY) completed the first sale of the blood-based ColoSTAT colorectal cancer test, according to a Wednesday filing with the Australian bourse.
The company will scale up test volumes directly with physicians and through its ColoSTAT Access Program, the filing said.
Shares rose nearly 13% in morning trade Wednesday.